The earnings call reflected a strong quarter for Guardant Health with significant revenue growth, successful product launches, and improved gross margins. Despite some uncertainties regarding the timing of Shield V2 data and Medicare reimbursement processes, the company's strong performance and raised revenue guidance indicate a positive outlook.

Company Guidance

During the Guardant Health Q2 2025 Earnings Conference Call, management provided updated guidance reflecting strong performance across various business lines. Total revenue for the quarter grew 31% year-over-year to $232.1 million, driven by oncology revenue growth of 22% to $158.7 million and record biopharma and data business revenue of $56 million, an increase of 28%. The company's screening revenue totaled $14.8 million, supported by the Shield testing revenue of $15 million from approximately 16,000 tests. The company raised its full-year 2025 revenue guidance to $915 million to $925 million, reflecting a growth of approximately 24% to 25% compared to 2024. Oncology volume grew 30% year-over-year, with Guardant360 Liquid and Tissue tests showing significant adoption. Shield ASP increased to over $900 in Q2, with Shield non-GAAP gross margin improving to 48%. Non-GAAP gross profit rose 44% year-over-year to $153.8 million, achieving a non-GAAP gross margin of 66%. The company continues to invest in expanding its commercial infrastructure, expecting to surpass 250 sales reps by year-end. Guardant Health aims to reach company-wide cash flow breakeven by 2028, maintaining a focus on reducing cash burn each year.

Record-Breaking Revenue Growth

Q2 revenue grew 31% year-over-year to $232 million, with strong performance across oncology, screening, and biopharma and data businesses.

Strong Oncology Business Performance

Oncology revenue increased 22% to $159 million, with oncology volumes increasing 30% year-over-year to approximately 64,000 tests.

Significant Growth in Guardant360 Liquid

Guardant360 Liquid saw over 20% year-over-year growth, marking the fourth consecutive quarter of accelerated growth.

Biopharma Business Achievements

Record biopharma business volume and revenue with second quarter revenue growing 28% year-over-year. Signed 2 new companion diagnostic deals in Q2.

Shield Testing Revenue and Development

Delivered $15 million of Shield testing revenue in Q2 from approximately 16,000 tests. Shield received NCCN guideline inclusion and high adherence rates over 90%.

Improved Gross Margins

Non-GAAP gross margin of 66%, a significant improvement from the previous year’s 60%, driven by improved oncology ASPs and increased Shield gross margins.

Positive Adjusted EBITDA Trend

Adjusted EBITDA loss reduced to $51.9 million for Q2 2025, an improvement of $10 million compared to a loss of $61.9 million in Q2 2024.

Raised Full Year 2025 Revenue Guidance

Full year 2025 revenue guidance increased to $915 million to $925 million from the previous range of $880 million to $890 million.

Guardant Health (GH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.79 / -	-0.88	―	―	―
Jul 30, 2025	2025 (Q2)	-0.74 / -0.80	-0.84	4.76% (+0.04)
Apr 30, 2025	2025 (Q1)	-0.79 / -0.77	-0.94	18.09% (+0.17)
Feb 20, 2025	2024 (Q4)	-0.78 / -0.90	-1.58	43.04% (+0.68)
Nov 06, 2024	2024 (Q3)	-0.73 / -0.88	-0.73	-20.55% (-0.15)
Aug 07, 2024	2024 (Q2)	-0.75 / -0.84	-0.67	-25.37% (-0.17)
May 09, 2024	2024 (Q1)	-0.88 / -0.94	-1.3	27.69% (+0.36)
Feb 22, 2024	2023 (Q4)	-0.86 / -1.58	-1.36	-16.18% (-0.22)
Nov 06, 2023	2023 (Q3)	-0.97 / -0.73	-1.58	53.80% (+0.85)
Aug 03, 2023	2023 (Q2)	-1.22 / -0.67	-2.25	70.22% (+1.58)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$45.19	$40.98	-9.32%
Apr 30, 2025	$47.23	$48.87	+3.47%
Feb 20, 2025	$47.40	$42.87	-9.56%
Nov 06, 2024	$25.29	$28.59	+13.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Guardant Health (GH) report earnings?

Guardant Health (GH) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Guardant Health (GH) earnings time?

Guardant Health (GH) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GH EPS forecast?

GH EPS forecast for the fiscal quarter 2025 (Q3) is -0.79.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing